OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)

被引：0
|
作者：
Corman, J. [1 ]
Dawson, N. [2 ]
Hall, S. [3 ]
Nabhan, C. [4 ]
Ferrari, A. [5 ]
Armstrong, A. J. [6 ]
Murdock, M. I. [7 ]
Stewart, F. [8 ]
Sheikh, N. [9 ]
Petrylak, D. P. [10 ]
机构：
[1] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[2] Georgetown Univ, Washington, WA USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
[5] NYU, Ctr Canc, New York, NY USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
[7] Murdock Urol Associates, Urol, Greenbelt, MD USA
[8] Dendreon Corp, Biometr, Seattle, WA USA
[9] Dendreon Corp, Clin Immunol, Seattle, WA USA
[10] Columbia Univ, Med Ctr, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
  • [31] A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
    Karzai, Fatima
    Madan, Ravi Amrit
    Owens, Helen
    Couvillon, Anna
    Hankin, Amy
    Williams, Monique
    Bilusic, Marijo
    Cordes, Lisa M.
    Trepel, Jane B.
    Killian, Keith
    Meltzer, Paul S.
    Gulley, James L.
    Lee, Jung-min
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [32] Impact of salvage therapy with APC8015F on the overall survival (OS) benefit achieved with sipuleucel-T in three phase III studies of metastatic castrate-resistant prostate cancer (mCRPC)
    Gomella, Leonard G.
    Nabhan, Chadi
    DeVries, Todd
    Whitmore, James Boyd
    Frohlich, Mark Walter
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] IMPACT OF SALVAGE THERAPY WITH APC8015F ON THE OVERALL SURVIVAL (OS) BENEFIT ACHIEVED WITH SIPULEUCEL-T IN THREE PHASE 3 STUDIES OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
    George, D. J.
    Gomella, L. G.
    Devries, T.
    Whitmore, J. B.
    Frohlich, M. W.
    Nabhan, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 310 - 310
  • [34] Evaluation of patients, safety, and financial implications of sipuleucel-T (SipT) for treatment of metastatic castrate-resistant prostate cancer (mCRPC): Early real-world experience at USC.
    Pak, S.
    Reed, M.
    Luther, M.
    Averia, M.
    Desai, S.
    Pinski, J. K.
    Dorff, T. B.
    Quinn, D. I.
    Chan, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Sipuleucel-T In Metastatic Castration-Resistant Prostate Cancer
    Plosker, Greg L.
    DRUGS, 2011, 71 (01) : 101 - 108
  • [36] Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study
    Gardner, Thomas A.
    Petrylak, Daniel Peter
    Corman, John M.
    Hall, Simon
    Weinstein, Ralph
    Keyser, Robert
    Sims, Robert Brownell
    Sanders, Amanda
    Sheikh, Nadeem A.
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [37] Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer (CRPC).
    Park, Jong Chul
    Sartor, A. Oliver
    Sullivan, Rana
    King, Serina
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Time to disease-related pain (TDRP) following sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Integrated results from three randomized phase 3 trials
    Small, E. J.
    Higano, C. S.
    Kantoff, P. W.
    Whitmore, J. B.
    Frohlich, M. W.
    Petrylak, D. P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E123 - U509
  • [39] Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).
    Kohli, Manish
    Huang, Xiaoyi
    Yuan, Tiezheng
    Sun, Zhifu
    Costello, Brian Addis
    Quevedo, Fernando
    Tan, Winston
    Nandy, Debashis
    Longenbach, Sherri
    Wang, Liang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [40] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
12345